Peterlin, P., Gaschet, J., Turlure, P., Gourin, M.-P., Dumas, P.-Y., Thepot, S., Berceanu, A., Park, S., Hospital, M.-A., Cluzeau, T., Torregrosa-Diaz, J.-M., Drevon, L., Sapena, R., Chermat, F., Ades, L., Dimicoli-Salazar, S., Jullien, M., Fenaux, P. and Chevallier., P. (2020) “FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2024.286025.